Modulation of ErbB2 blockade in ErbB2-positive cancers

The role of ErbB2 mutations and PHLDA1

Guangyuan Li, Xiaoqi Wang, Hanina Hibshoosh, Cheng Jin, Balazs Halmos

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We set out to study the key effectors of resistance and sensitivity to ErbB2 tyrosine kinase inhibitors, such as lapatinib in ErbB2-positive breast and lung cancers. A cell-based in vitro site-directed mutagenesis lapatinib resistance model identified several mutations, including the gatekeeper ErbB2 mutation ErbB2-T798I, as mediating resistance. ErbB2-T798I engineered cell models indeed show resistance to lapatinib but remain sensitive to the irreversible EGFR/ErbB2 inhibitor, PD168393, suggestive of potential alternative treatment strategies to overcome resistance. Gene expression profiling studies identified a select group of downstream targets regulated by ErbB2 signaling and define PHLDA1 as an immediately downregulated gene upon oncogenic ErbB2 signaling inhibition. We find significant down-regulation of PHLDA1 in primary breast cancer and PHLDA1 is statistically significantly less expressed in ErbB2 negative compared with ErbB2 positive tumors consistent with its regulation by ErbB2. Lastly, PHLDA1 overexpression blocks AKT signaling, inhibits cell growth and enhances lapatinib sensitivity further supporting an important negative growth regulator function. Our findings suggest that PHLDA1 might have key inhibitory functions in ErbB2 driven lung and breast cancer cells and a better understanding of its functions might point at novel therapeutic options. In summary, our studies define novel ways of modulating sensitivity and resistance to ErbB2 inhibition in ErbB2-dependent cancers.

Original languageEnglish (US)
Article numbere106349
JournalPLoS One
Volume9
Issue number9
DOIs
StatePublished - Sep 19 2014
Externally publishedYes

Fingerprint

breast neoplasms
Modulation
lung neoplasms
mutation
Mutation
neoplasms
Breast Neoplasms
Lung Neoplasms
Neoplasms
Down-Regulation
site-directed mutagenesis
growth regulators
Mutagenesis
tyrosine
cell growth
phosphotransferases (kinases)
Cell growth
Gene Expression Profiling
Growth
Site-Directed Mutagenesis

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Modulation of ErbB2 blockade in ErbB2-positive cancers : The role of ErbB2 mutations and PHLDA1. / Li, Guangyuan; Wang, Xiaoqi; Hibshoosh, Hanina; Jin, Cheng; Halmos, Balazs.

In: PLoS One, Vol. 9, No. 9, e106349, 19.09.2014.

Research output: Contribution to journalArticle

Li, Guangyuan ; Wang, Xiaoqi ; Hibshoosh, Hanina ; Jin, Cheng ; Halmos, Balazs. / Modulation of ErbB2 blockade in ErbB2-positive cancers : The role of ErbB2 mutations and PHLDA1. In: PLoS One. 2014 ; Vol. 9, No. 9.
@article{193778ed4de44ba9b69e67fa8987c2ce,
title = "Modulation of ErbB2 blockade in ErbB2-positive cancers: The role of ErbB2 mutations and PHLDA1",
abstract = "We set out to study the key effectors of resistance and sensitivity to ErbB2 tyrosine kinase inhibitors, such as lapatinib in ErbB2-positive breast and lung cancers. A cell-based in vitro site-directed mutagenesis lapatinib resistance model identified several mutations, including the gatekeeper ErbB2 mutation ErbB2-T798I, as mediating resistance. ErbB2-T798I engineered cell models indeed show resistance to lapatinib but remain sensitive to the irreversible EGFR/ErbB2 inhibitor, PD168393, suggestive of potential alternative treatment strategies to overcome resistance. Gene expression profiling studies identified a select group of downstream targets regulated by ErbB2 signaling and define PHLDA1 as an immediately downregulated gene upon oncogenic ErbB2 signaling inhibition. We find significant down-regulation of PHLDA1 in primary breast cancer and PHLDA1 is statistically significantly less expressed in ErbB2 negative compared with ErbB2 positive tumors consistent with its regulation by ErbB2. Lastly, PHLDA1 overexpression blocks AKT signaling, inhibits cell growth and enhances lapatinib sensitivity further supporting an important negative growth regulator function. Our findings suggest that PHLDA1 might have key inhibitory functions in ErbB2 driven lung and breast cancer cells and a better understanding of its functions might point at novel therapeutic options. In summary, our studies define novel ways of modulating sensitivity and resistance to ErbB2 inhibition in ErbB2-dependent cancers.",
author = "Guangyuan Li and Xiaoqi Wang and Hanina Hibshoosh and Cheng Jin and Balazs Halmos",
year = "2014",
month = "9",
day = "19",
doi = "10.1371/journal.pone.0106349",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - Modulation of ErbB2 blockade in ErbB2-positive cancers

T2 - The role of ErbB2 mutations and PHLDA1

AU - Li, Guangyuan

AU - Wang, Xiaoqi

AU - Hibshoosh, Hanina

AU - Jin, Cheng

AU - Halmos, Balazs

PY - 2014/9/19

Y1 - 2014/9/19

N2 - We set out to study the key effectors of resistance and sensitivity to ErbB2 tyrosine kinase inhibitors, such as lapatinib in ErbB2-positive breast and lung cancers. A cell-based in vitro site-directed mutagenesis lapatinib resistance model identified several mutations, including the gatekeeper ErbB2 mutation ErbB2-T798I, as mediating resistance. ErbB2-T798I engineered cell models indeed show resistance to lapatinib but remain sensitive to the irreversible EGFR/ErbB2 inhibitor, PD168393, suggestive of potential alternative treatment strategies to overcome resistance. Gene expression profiling studies identified a select group of downstream targets regulated by ErbB2 signaling and define PHLDA1 as an immediately downregulated gene upon oncogenic ErbB2 signaling inhibition. We find significant down-regulation of PHLDA1 in primary breast cancer and PHLDA1 is statistically significantly less expressed in ErbB2 negative compared with ErbB2 positive tumors consistent with its regulation by ErbB2. Lastly, PHLDA1 overexpression blocks AKT signaling, inhibits cell growth and enhances lapatinib sensitivity further supporting an important negative growth regulator function. Our findings suggest that PHLDA1 might have key inhibitory functions in ErbB2 driven lung and breast cancer cells and a better understanding of its functions might point at novel therapeutic options. In summary, our studies define novel ways of modulating sensitivity and resistance to ErbB2 inhibition in ErbB2-dependent cancers.

AB - We set out to study the key effectors of resistance and sensitivity to ErbB2 tyrosine kinase inhibitors, such as lapatinib in ErbB2-positive breast and lung cancers. A cell-based in vitro site-directed mutagenesis lapatinib resistance model identified several mutations, including the gatekeeper ErbB2 mutation ErbB2-T798I, as mediating resistance. ErbB2-T798I engineered cell models indeed show resistance to lapatinib but remain sensitive to the irreversible EGFR/ErbB2 inhibitor, PD168393, suggestive of potential alternative treatment strategies to overcome resistance. Gene expression profiling studies identified a select group of downstream targets regulated by ErbB2 signaling and define PHLDA1 as an immediately downregulated gene upon oncogenic ErbB2 signaling inhibition. We find significant down-regulation of PHLDA1 in primary breast cancer and PHLDA1 is statistically significantly less expressed in ErbB2 negative compared with ErbB2 positive tumors consistent with its regulation by ErbB2. Lastly, PHLDA1 overexpression blocks AKT signaling, inhibits cell growth and enhances lapatinib sensitivity further supporting an important negative growth regulator function. Our findings suggest that PHLDA1 might have key inhibitory functions in ErbB2 driven lung and breast cancer cells and a better understanding of its functions might point at novel therapeutic options. In summary, our studies define novel ways of modulating sensitivity and resistance to ErbB2 inhibition in ErbB2-dependent cancers.

UR - http://www.scopus.com/inward/record.url?scp=84907200604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907200604&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0106349

DO - 10.1371/journal.pone.0106349

M3 - Article

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e106349

ER -